This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 7 for:    Cirmtuzumab
Previous Study | Return to List | Next Study

Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05156905
Recruitment Status : Recruiting
First Posted : December 14, 2021
Last Update Posted : November 13, 2023
Sponsor:
Information provided by (Responsible Party):
Rana Mckay, University of California, San Diego

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to examine the safety and efficacy of cirmtuzumab in combination with standard of care docetaxel in patients with metastatic castration resistant prostate cancer. Docetaxel is a taxane chemotherapy which has been shown to prolong survival in men with castration resistant prostate cancer. Cirmtuzumab is a monoclonal antibody that targets the receptor called ROR1 of the non-canonical Wnt pathway and is suspected to contribute to prostate cancer growth and progression.

Condition or disease Intervention/treatment Phase
Metastatic Castration-resistant Prostate Cancer Drug: Cirmtuzumab Phase 1

Detailed Description:
This study seeks to targeting the non-canonical Wnt pathway with an antibody against ROR1. ROR1 is an attractive target given its low expression in non-malignant tissues and its role in proliferation and survival in prostate cancer. From preclinical data in a variety of tumor types, blockade of ROR1 inhibits cell growth and cirmtuzumab has shown efficacy in clinical trials with CLL. Preclinical data suggests that ROR1 is upregulated in chemotherapy resistant cells and treatment with cirmtuzumab and a taxane achieved higher cytotoxic response than both agents alone, supporting the use of the combination of cirmtuzumab and a taxane. Based on the biological rationale behind cirmtuzumab and preclinical activity with docetaxel, this is an open label, phase 2 clinical trial to evaluate the safety and efficacy of cirmtuzumab in combination with docetaxel for the treatment of metastatic, castrate resistant prostate adenocarcinoma.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Trial Investigating Docetaxel Combined With Cirmtuzumab in Patients With Metastatic Castration Resistant Prostate Cancer
Actual Study Start Date : June 16, 2022
Estimated Primary Completion Date : February 2025
Estimated Study Completion Date : February 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Docetaxel

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Cirmtuzumab + Docetaxel
There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
 Drug: Cirmtuzumab
Cirmtuzumab will be given in combination with docetaxel.
Other Name: Docetaxel


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Recommended phase 2 dose of docetaxel combined with cirmtuzumab [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined by CTCAE version 5 grading


Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined by CTCAE version 5 grading

  2. Total alkaline phosphatase response [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined as a reduction of ≥30% from the baseline value, confirmed ≥4 weeks later.

  3. Time to PSA progression [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined by PCWG-3 criteria

  4. Time to increase in the total alkaline phosphatase level [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined as an increase of ≥25% from baseline at ≥12 weeks, in patients with no decrease from baseline, or as an increase of ≥25% above the nadir, confirmed ≥3 weeks later, in patients with an initial decrease from baseline.

  5. Radiographic progression free survival [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Defined by PCWG-3 criteria for bone metastases and RECIST version 1.1 for soft tissue

  6. Time to first subsequent anti-cancer therapy [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Time from study discontinuation to initiation of subsequent systemic anti-cancer therapy or death

  7. Time to first symptomatic skeletal event [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Time to first symptomatic pathologic fracture, radiation to the bone given symptomatic bone metastasis, surgery to the bone given symptomatic bone metastasis, or symptomatic spinal cord compression

  8. Overall survival [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Time from enrollment to death or last follow up

  9. Composite clinical benefit [ Time Frame: Patients will be followed from study entry to death or date last known alive, assessed up to 36 months ]
    Composite endpoint of clinical benefit defined as any one of the following: PSA response by PCWG3 criteria, objective response rate by RECIST version 1.1, and stable disease > 6 months by RECIST version 1.1.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate. Patients with neuroendocrine component are eligible.
  2. Participants must have castrate levels of serum testosterone < 50 ng/dL.
  3. Participants without orchiectomy must be maintained on luteinizing hormone releasing hormone (LHRH) agonist/antagonist.
  4. Participants must have received prior abiraterone and/or next generation androgen receptor antagonist (enzalutamide, apalutamide, or darolutamide) for hormone sensitive disease or CRPC. Prior docetaxel for hormone sensitive disease is permitted.
  5. Participants must have progressive disease. Patients with non-measurable disease are eligible.
  6. Eastern Cooperative Oncology Group performance status ≤1 (Karnofsky ≥80%).
  7. Patients must have normal organ and marrow function.

Exclusion Criteria:

  1. No pure small cell carcinoma.
  2. Prior treatment with cirmtuzumab.
  3. No prior treatment with docetaxel for CRPC.
  4. Treatment with abiraterone, apalutamide, or darolutamide within 2 weeks of treatment initiation. Treatment with cytotoxic chemotherapy within 3 weeks of treatment initiation. Treatment enzalutamide or other investigational prostate cancer directed therapy within 4 weeks of treatment initiation.
  5. Palliative radiation therapy to the bone or other sites within 2 weeks of treatment initiation.
  6. Imminent or established spinal cord compression based on clinical and/or imaging findings.
  7. Known active central nervous system metastases and/or carcinomatous meningitis.
  8. Uncontrolled intercurrent illness or clinically significant medical condition.
  9. Treatment with antimicrobial agent within 4 weeks of treatment initiation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05156905


Contacts
Layout table for location contacts
Contact: Rana R McKay, MD 858-822-6185 rmckay@health.ucsd.edu

Locations
Layout table for location information
United States, California
University of California San Diego Recruiting
La Jolla, California, United States, 92037
Contact: Rana R McKay, MD    858-822-6185    rmckay@health.ucsd.edu   
Sponsors and Collaborators
University of California, San Diego
Investigators
Layout table for investigator information
Study Chair: Rana McKay UCSD
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Rana Mckay, Associate Professor of Medicine and Urology, University of California, San Diego
ClinicalTrials.gov Identifier: NCT05156905    
Other Study ID Numbers: 19-1514
First Posted: December 14, 2021    Key Record Dates
Last Update Posted: November 13, 2023
Last Verified: November 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Rana Mckay, University of California, San Diego:
Prostate cancer
Docetaxel
Wnt pathway
Cirmtuzumab
ROR1
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
 Prostatic Diseases
Male Urogenital Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action